Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

Pediatr Dermatol. 2022 Sep;39(5):764-766. doi: 10.1111/pde.15044. Epub 2022 Jun 23.

Abstract

Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11-year-old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor.

Keywords: NF1; elephantiasis neuromatosa; neurofibromatosis; plexiform neurofibroma; selumetinib.

Publication types

  • Case Reports

MeSH terms

  • Benzimidazoles
  • Child
  • Elephantiasis* / complications
  • Female
  • Humans
  • Mitogen-Activated Protein Kinase Kinases / therapeutic use
  • Neurofibroma, Plexiform* / complications
  • Neurofibroma, Plexiform* / drug therapy
  • Neurofibromatosis 1* / complications
  • Neurofibromatosis 1* / drug therapy

Substances

  • AZD 6244
  • Benzimidazoles
  • Mitogen-Activated Protein Kinase Kinases